SYRE FY2025 SEC EDGAR DEF 14A #166 of 168 in industry

Spyre Therapeutics, Inc. CEO pay ratio

The CEO earned $437K in FY2025 against median worker pay of $437,242 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-10
Industry
Chemicals & Pharmaceuticals
Industry rank
#166/168

Data updated August 2026

Subscribe to Spyre Therapeutics, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
1:1
Below Average (Scale: 0–1000:1)
CEO pay
$437K
Median worker
$437,242

Answer first

Spyre Therapeutics, Inc.'s FY2025 CEO total of $437K ranks #1287 of 1,423 complete filings; its 1:1 pay ratio ranks #1415. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $437,242. Industry placement uses the FY2025 SIC-28 peer cohort (# 166 of 168, 2nd percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1287
$437K of 1,423 FY2025
Ratio rank
#1415
1:1 of 1,423
Industry pct
2nd
among the lower quartile of industry peers by pay ratio

How Spyre Therapeutics, Inc. ranks nationally

Spyre Therapeutics, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$437,242 10th percentile higher than 10% of 1,423 companies

$0–$2,500,000: 304 companies (21%). This entry sits in this band. $2,500,000–$5,000,000: 182 companies (13%). Above this entry. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Spyre Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($437K) against pay ratio (1:1) for Spyre Therapeutics, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02798065.35596130.68394195.911192261.30:111.0:122.0:133.0:144.0:1CEO total payPay ratio (CEO : median worker)Spyre Therapeutics, Inc., CEO total pay: 437242 · Pay ratio (CEO : median worker): 1:1Spyre Therapeutics, Inc.Vanda Pharmaceuticals Inc., CEO total pay: 3851468 · Pay ratio (CEO : median worker): 1:1Vanda Pharmaceuticals Inc.Zai Lab Ltd, CEO total pay: 10677221 · Pay ratio (CEO : median worker): 1:1Zai Lab LtdTwist Bioscience Corp, CEO total pay: 376416 · Pay ratio (CEO : median worker): 2:1Twist Bioscience CorpSummit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.
Spyre Therapeutics, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Spyre Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
1:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$437K
Companies in Industry
168
vs. Industry Median
Below
#166 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Spyre Therapeutics, Inc.: near-parity Item 402(u) ratio

Spyre Therapeutics, Inc.'s FY2025 ratio 1:1 ranks #166 of 168 Chemicals & Pharmaceuticals filers (2nd percentile). the CEO earned 1× the median employee ($437,242) in FY2025.

At $437,242 median worker pay, the PARITY stamp is near pay-parity territory under MICRO CEO total.

CEO Total Pay

$437K

FY2025 Summary Compensation, below median

Pay Ratio

1:1

Below typical

Spyre Therapeutics, Inc. in the lower Chemicals & Pharmaceuticals third

Spyre Therapeutics, Inc.'s FY2025 ratio 1:1 ranks #166 of 168 Chemicals & Pharmaceuticals filers (2nd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Spyre Therapeutics, Inc.'s $437K CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1287 and ratio rank #1415 split - treat 1:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$437K
Median Employee Pay
$437,242
Pay Ratio
1:1
Filing Date
2026-04-10

Company Info

Ticker
SYRE
CIK
1636282
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1636282, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Spyre Therapeutics, Inc.'s FY2025 ratio 1:1 ranks #166 of 168 Chemicals & Pharmaceuticals filers (2nd percentile).

Read with Spyre Therapeutics, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps PARITY · MICRO · ELITE-MED.

Oscar Health, Inc. · MICRO

ABS(ceo_total_comp) peer at $441K (Δ $3K heavier vs Spyre Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's PARITY · MICRO · ELITE-MED.
Edgewise Therapeutics, Inc. · MICRO

ABS(ceo_total_comp) peer at $444K (Δ $6K heavier vs Spyre Therapeutics, Inc.); FLOOR · ELITE-MED vs this page's PARITY · MICRO · ELITE-MED.
Telephone & Data Systems Inc /de/ · MICRO

ABS(ceo_total_comp) peer at $453K (Δ $16K heavier vs Spyre Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's PARITY · MICRO · ELITE-MED.
Celanese Corp · MICRO

ABS(ceo_total_comp) peer at $463K (Δ $25K heavier vs Spyre Therapeutics, Inc.); FLOOR · HIGH-MED vs this page's PARITY · MICRO · ELITE-MED.
Vanda Pharmaceuticals Inc. (SIC 28 pole)

Vanda Pharmaceuticals Inc. stamps PARITY · MID$ nearest in-SIC by ABS(pay_ratio) to Spyre Therapeutics, Inc.'s PARITY filing.
National dual ranks · #1287/#1415

Spyre Therapeutics, Inc.'s FY2025 package sits #1287 by CEO dollars and #1415 by ratio under MICRO · PARITY.
Ratio primer · PARITY

Spyre Therapeutics, Inc.'s PARITY stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Spyre Therapeutics, Inc. (CIK 1636282), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.